FDG PET for predicting anal cancer treatment outcome

A new biomarker (ZMP) for predicting treatment outcome of squamous cell carcinomas of the anal canal has been evaluated. The metric was based on [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) images of patients treated with definitive chemoradiotherapy. The impact of the new metric on locoregional control was assessed by comparing it to other PET-based metrics and clinicopathological prognostic factors, such as TNM stage and human papilloma virus (HPV) status.